Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$439.64 0.27 (0.06)%

High 443.00 Low 438.00 Volume 309,281 Market Cap 45.89B
10/19/17 2:02 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Oct 16

    Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis

    Read on
  • Oct 11

    Regeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017

    Read on

EVENTS

  • Regeneron Pharmaceuticals Q3 2017 Earnings Conference Call
    Nov 8, 2017 | 8:30 AM ET

Events & Presentations

NASDAQ REGN

$439.64 0.27 (0.06)%

High 443.00 Low 438.00 Volume 309,281 Market Cap 45.89B
10/19/17 2:02 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information